Roche co-led a round for AveXis that will help fund development of its spinal muscular atrophy treatment.
US-based biotechnology company AveXis completed a $10m series C round co-led by Roche Venture Fund, the corporate venturing unit of pharmaceutical company Roche, and investment firm Deerfield Management on Thursday.
AveXis previously raised an undisclosed amount of series B funding in April 2014 from another investment firm, PBM Capital, but has not disclosed details concerning its series A round.
AveXis is developing a gene therapy product dubbed ChariSMA, which is intended to ttreat genetic and orphan diseases such as spinal…
